Cationic Amphiphilic Drugs Boost the Lysosomal Escape of Small Nucleic Acid Therapeutics in a Nanocarrier-Dependent Manner
- 6 April 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 14 (4), 4774-4791
- https://doi.org/10.1021/acsnano.0c00666
Abstract
Small nucleic acid (NA) therapeutics, such as small interfering RNA (siRNA), are generally formulated in nanoparticles (NPs) to overcome the multiple extra- and intracellular barriers upon in vivo administration. Interaction with target cells typically triggers endocytosis and sequesters the NPs in endosomes, thus hampering the pharmacological activity of the encapsulated siRNAs that occurs in the cytosol. Unfortunately, for most state-of-the-art NPs, endosomal escape is largely inefficient. As a result, the bulk of the endocytosed NA drug is rapidly trafficked towards the degradative lysosomes that are considered as a dead-end for siRNA nanomedicines. Opposed to this paradigm, we recently reported that cationic amphiphilic drugs (CADs) could strongly promote functional siRNA delivery from the endolysosomal compartment via transient induction of lysosomal membrane permeabilization. However, many questions still remain regarding the broader applicability of such a CAD adjuvant effect on NA delivery. Here, we report a drug repurposing screen (National Institutes of Health Clinical Collection) that allowed identification of 56 CAD adjuvants. We furthermore demonstrate that the CAD adjuvant effect is dependent on the type of nanocarrier, with NPs that generate an appropriate pool of decomplexed siRNA in the endolysosomal compartment being most susceptible to CAD-promoted gene silencing. Finally, the CAD adjuvant effect was verified on human ovarian cancer cells and for antisense oligonucleotides. In conclusion, this study strongly expands our current knowledge on how CADs increase the cytosolic release of small NAs, providing relevant insights to more rationally combine CAD adjuvants with NA-loaded NPs for future therapeutic applications.Keywords
Funding Information
- H2020 Marie Sklodowska-Curie Actions (676137)
- Fonds Wetenschappelijk Onderzoek (1198719N, 1517516N, 1S30618N, 1S62519N, 1S75019N)
- Agentschap voor Innovatie door Wetenschap en Technologie
- Bijzonder Onderzoeksfonds (BOF12/GOA/014)
This publication has 107 references indexed in Scilit:
- Identification of Drugs Inducing Phospholipidosis by Novel in vitro DataChemMedChem, 2012
- Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**Angewandte Chemie, 2012
- PEGylation of biodegradable dextran nanogels for siRNA deliveryEuropean Journal of Pharmaceutical Sciences, 2010
- Biodegradable Dextran Nanogels for RNA Interference: Focusing on Endosomal Escape and Intracellular siRNA DeliveryAdvanced Functional Materials, 2009
- Effect of Protein Binding on the Pharmacological Activity of Highly Bound AntibioticsAntimicrobial Agents and Chemotherapy, 2008
- Lysosomal membrane permeabilization in cell deathOncogene, 2008
- Quantitative modeling of selective lysosomal targeting for drug designEuropean Biophysics Journal, 2008
- Improved silencing properties using small internally segmented interfering RNAsNucleic Acids Research, 2007
- Photochemically Induced Gene Silencing Using Small Interfering RNA Molecules in Combination with Lipid CarriersOligonucleotides, 2007
- Amiodarone toxicity *1II. Desethylamiodarone-induced phospholipidosis and ultrastructural changes during repeated administration in ratsFundamental and Applied Toxicology, 1991